Literature DB >> 7339069

Research on the production site of tumor necrosis factor (TNF).

N Satomi, K Haranaka, O Kunii.   

Abstract

Tumor Necrosis Factor (TNF) is an active component of serum taken from Corynebacterium parvum (C. parvum) infected mice treated with lipopolysaccharide (LPS). To locate the production site of TNF, we tried to block TNF production by using the following reagents; carrageenan, hydrocortisone, and trypan blue. Following the injection of a large dose of carrageenan, administered before C. parvum treatment, TNF production was completely blocked. However, when administered after C. parvum treatment but prior to LPS injection, no blockage was observed. Injecting hydrocortisone before the LPS injection also blocked TNF release. However, this treatment, when administered before the injection of C. parvum, had no observable influence on TNF production. A large dose of trypan blue, administered before the LPS injection, also blocked the release of TNF. A low dose of trypan blue resulted in only partial blockage of TNF production. A large dose of trypan blue, administered prior to C. parvum treatment, also showed partial blockage of TNF production. Macrophage-enriched peritoneal exudate cells (PEC), taken from mice infected with C. parvum, released TNF into the supernatant after stimulation with LPS. These results strongly suggest that the production site of TNF is located within the activated macrophage and deeply related with lysosome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7339069

Source DB:  PubMed          Journal:  Jpn J Exp Med        ISSN: 0021-5031


  9 in total

1.  Recombinant interleukin-1 and tumor necrosis factor induce neutrophil migration "in vivo" by indirect mechanisms.

Authors:  L H Faccioli; G E Souza; F Q Cunha; S Poole; S H Ferreira
Journal:  Agents Actions       Date:  1990-06

2.  Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor.

Authors:  K Haranaka; E A Carswell; B D Williamson; J S Prendergast; N Satomi; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Tumour necrosis factor and the lysosomal enzymes of macrophages or macrophage-like cell line.

Authors:  A Sakurai; N Satomi; K Haranaka
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka; N Okada; M Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Enhancement of lipopolysaccharide-induced tumor necrosis factor production in mice by carrageenan pretreatment.

Authors:  M Ogata; S Yoshida; M Kamochi; A Shigematsu; Y Mizuguchi
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

6.  Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships.

Authors:  Y Natsuhara; S Oka; K Kaneda; Y Kato; I Yano
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Role of first stimulating agents in the production of tumor necrosis factor.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours.

Authors:  P Shah; P H van der Meide; T Borman; N Schroeder; J M Bliss; R C Coombes
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

9.  Differences in tumour necrosis factor productive ability among rodents.

Authors:  K Haranaka; N Satomi; A Sakurai
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.